Zydus Lifesciences (formerly known as Cadila Healthcare) has announced the launch of Bemdac (Bempedoic acid), a new class of drug for the first time in India.

The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management.

LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases.

Speaking on the development, Dr Sharvil Patel, Managing Director, Zydus Lifesciences said “With Bemdac, we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c. Bemdac is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol. Our mission is to empower patients with a better quality of life through effective disease management and with Bemdac we have taken a great leap ahead in this endeavour.”